Ranbaxy Laboratories, the domestic pharma major, has got the Good Manufacturing Practice certificate from the Ministry of Health and Labour Welfare - Japan for its non-sterile drug plant at Dewas in India.
The approval has been granted for a period of five years and will cover all products that are currently manufactured at this site and that will be filed in the future for Japan.
On the Bombay Stock Exchange, the company's shares last traded at Rs 274.40 on Thursday, up 2.22 per cent.
